前列腺癌盆腔淋巴结调强放疗的1/2期剂量递增研究
该1/2期研究纳入447例晚期局限期前列腺癌患者,评估盆腔淋巴结调强放疗(PLN-IMRT)剂量递增及大分割的可行性。主要终点为放疗后2年晚期RTOG毒性。结果显示PLN-IMRT安全可耐受,全组5年生化/临床无失败率为71%,盆腔淋巴结控制率94%。
要点
- PLN-IMRT剂量递增至60 Gy(35-37次)及大分割(47 Gy/20次)均安全可耐受。
- 2年≥2级肠道毒性各队列为8.3%-16.4%,膀胱毒性为2.9%-7.3%。
- 全组5年生化/临床无失败率71%,盆腔淋巴结控制率94%。
核心结论
- PLN-IMRT安全且耐受性良好,但需3期研究验证疗效是否可抵消轻度肠道副作用增加。
研究设计与样本
- 1/2期剂量递增研究,2000年8月至2010年6月纳入447例晚期局限期前列腺癌患者,中位随访90个月。
主要发现
- 2年≥2级肠道/膀胱毒性:队列1为8.3%/4.2%(95%CI 2.2%-29.4%/0.6%-26.1%),队列2为8.9%/5.9%(4.1%-18.7%/2.3%-15.0%),队列3为13.2%/2.9%(8.6%-20.2%/1.1%-7.7%),队列4为16.4%/4.8%(9.2%-28.4%/1.6%-14.3%),队列5为12.2%/7.3%(7.6%-19.5%/3.9%-13.6%)。
- 肠道和膀胱毒性患病率随时间保持稳定,其他量表结果一致。
- 全组5年生化/临床无失败率为71%(66%-75%),盆腔淋巴结控制率为94%。
关键数值与推荐
- 队列1-3:前列腺70-74 Gy,PLN-IMRT 50 Gy、55 Gy、60 Gy,35-37次。
- 队列4-5:前列腺60 Gy,PLN 47 Gy,20次,分别4周和5周完成。
- 所有患者接受长程雄激素剥夺治疗。
临床怎么用
- PLN-IMRT可用于晚期局限期前列腺癌的盆腔淋巴结预防性照射,剂量递增至60 Gy及大分割方案均可行。
- 需关注肠道毒性,尤其大分割队列4的2年≥2级肠道毒性达16.4%。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the feasibility of dose escalation and hypofractionation of pelvic lymph node intensity modulated radiation therapy (PLN-IMRT) in prostate cancer (PCa). METHODS AND MATERIALS: In a phase 1/2 study, patients with advanced localized PCa were sequentially treated with 70 to 74 Gy to the prostate and dose-escalating PLN-IMRT at doses of 50 Gy (cohort 1), 55 Gy (cohort 2), and 60 Gy (cohort 3) in 35 to 37 fractions. Two hypofractionated cohorts received 60 Gy to the prostate and 47 Gy to PLN in 20 fractions over 4 weeks (cohort 4) and 5 weeks (cohort 5). All patients received long-course androgen deprivation therapy. Primary outcome was late Radiation Therapy Oncology Group toxicity at 2 years after radiation therapy for all cohorts. Secondary outcomes were acute and late toxicity using other clinician/patient-reported instruments and treatment efficacy. RESULTS: Between August 9, 2000, and June 9, 2010, 447 patients were enrolled. Median follow-up was 90 months. The 2-year rates of grade 2+ bowel/bladder toxicity were as follows: cohort 1, 8.3%/4.2% (95% confidence interval 2.2%-29.4%/0.6%-26.1%); cohort 2, 8.9%/5.9% (4.1%-18.7%/2.3%-15.0%); cohort 3, 13.2%/2.9% (8.6%-20.2%/1.1%-7.7%); cohort 4, 16.4%/4.8% (9.2%-28.4%/1.6%-14.3%); cohort 5, 12.2%/7.3% (7.6%-19.5%/3.9%-13.6%). Prevalence of bowel and bladder toxicity seemed to be stable over time. Other scales mirrored these results. The biochemical/clinical failure-free rate was 71% (66%-75%) at 5 years for the whole group, with pelvic lymph node control in 94% of patients. CONCLUSIONS: This study shows the safety and tolerability of PLN-IMRT. Ongoing and planned phase 3 studies will need to demonstrate an increase in efficacy using PLN-IMRT to offset the small increase in bowel side effects compared with prostate-only IMRT.
引用
- Reis Ferreira M, Khan A, Thomas K, et al. Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28939224. doi:10.1016/j.ijrobp.2017.07.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。